OQS
BCLI

Occudo Quantitative Strategies’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Occudo Quantitative Strategies’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,626
Closed -$50.3K – 984
2023
Q2 		$50.3K Buy
+1,626
New +$67.4K 0.01% 959
2021
Q4 		– Sell
-678
Closed -$34K – 1066
2021
Q3 		$34K Buy
+678
New +$35.7K ﹤0.01% 978
2021
Q1 		– Sell
-6,039
Closed -$410K – 754
2020
Q4 		$410K Buy
+6,039
New +$822K 0.13% 307

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Occudo Quantitative Strategies's BCLI Position: Q3 2023 in Review

Occudo Quantitative Strategies sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2023, closing a stake of 1,626 shares — an estimated $50.3K sold.

Occudo Quantitative Strategies first reported a position in BCLI in Q4 2020 and held it in 3 quarters. The position peaked at $410K in Q4 2020. 53 funds tracked by Wall St. Rank hold BCLI as of Q3 2023.

  • Occudo Quantitative Strategies reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 1,626 BRAINSTORM CELL THERAPUTC shares in Q3 2023, an estimated $50.3K.
  • Occudo Quantitative Strategies first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 3 quarters.
  • Occudo Quantitative Strategies's BRAINSTORM CELL THERAPUTC position peaked at $410K in Q4 2020.
  • 53 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.